Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Dél-Korea
18 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Where
- Busan, Daejeon, Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 1046 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00 - 2. fázisTaking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - 3. fázisTaking peopleA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Where
- Busan, Daegu, Incheon, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 904 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00 - 2/3. fázisTaking peopleA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 290 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00 - 2. fázisTaking peopleStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Where
- Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon, Ulsan
- Életkor
- 65 év to 99 év
- People
- 80 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05952024 - 1/2. fázisTaking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Seoul
- Életkor
- 6 hónap to 25 év
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - 2. fázisTaking peopleConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Where
- Goyang-si, Hwasun, Seogu, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Allogene Therapeutics
See details and how to joinNCT06500273 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Daejeon, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- GangnamGu, SeochoGu, SeodaemunGu, Seogu, Seoul, SongpaGu
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Daegu, Goyang-si, Incheon, Seoul
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - No phaseTaking peopleLong-term Follow up Local Registry Study of Kymriah in South Korea
- Where
- Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, Ulsan
- Életkor
- 0 év to 100 év
- People
- 500
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06785818 - 1/2. fázisTaking peopleStudy of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 91
- Run by
- Curocell Inc.
See details and how to joinNCT04836507 - 2. fázisTaking peopleStudy of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 30
- Run by
- Kim, Seok Jin
See details and how to joinNCT04627753 - 1/2. fázisTaking peopleStudy of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 98
- Run by
- TICAROS Co., Ltd.
See details and how to joinNCT07473167 - 2. fázisTaking peopleAnbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 12
- Run by
- Hyungwoo Cho
See details and how to joinNCT07062627 - 1/2. fázisNot yet taking people in Dél-KoreaGolcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 20
- Run by
- Seoul National University Hospital
See details and how to joinNCT07269639 - No phaseTaking peopleImmunotherapy in Lymphoma
- Where
- Seoul
- Életkor
- 19 év to 74 év
- People
- 72
- Run by
- Sung-Soo Park
See details and how to joinNCT06796517 - 1/2. fázisTaking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Goyang, Incheon, Seoul
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394